Li-Kai Tsai1, Huey-Juan Lin2, Su-Kiat Chua3, Pen-Chih Liao4, Yuan-Po Yang5, Ping-Chen Chou6, Chun-Wei Lee7, Mao-Jen Lin8, Hsi-Ming Chen9, Jung-Tze Yeh10, Yi-Heng Li11. 1. Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. 2. Department of Neurology, Chi Mei Medical Center, Tainan, Taiwan. 3. Department of Internal Medicine, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan. 4. Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. 5. Cardiovascular Department, Changhua Christian Hospital, Changhua, Taiwan. 6. Department of Neurology, National Taiwan University Hospital Hsin Chu Branch, Hsinchu, Taiwan. 7. Department of Internal Medicine, Mackay Memorial Hospital Tamshui Branch, New Taipei City, Taiwan. 8. Department of Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan. 9. Department of Neurology, Ton Yen General Hospital, HsinChu, Taiwan. 10. Medical Department, Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan. 11. Department of Internal Medicine, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan. Electronic address: heng@mail.ncku.edu.tw.
Abstract
BACKGROUND: This study aims to observe the effectiveness and safety of idarucizumab in dabigatran-treated patients with severe bleeding or requiring surgery in Taiwan. METHODS AND RESULTS: In Taiwan, 11 dabigatran-treated patients developed severe bleeding, fracture that needed surgery, and acute ischemic stroke requiring thrombolysis. These patients were treated with idarucizumab and obtained adequate hemostasis. Our experiences reconfirmed the efficacy and safety of idarucizumab in Asian patients. CONCLUSIONS: Idarucizumab improves safety in dabigatran-treated patients. Continued education about the availability and appropriate use of idarucizumab is necessary in Asia.
BACKGROUND: This study aims to observe the effectiveness and safety of idarucizumab in dabigatran-treated patients with severe bleeding or requiring surgery in Taiwan. METHODS AND RESULTS: In Taiwan, 11 dabigatran-treated patients developed severe bleeding, fracture that needed surgery, and acute ischemic stroke requiring thrombolysis. These patients were treated with idarucizumab and obtained adequate hemostasis. Our experiences reconfirmed the efficacy and safety of idarucizumab in Asian patients. CONCLUSIONS:Idarucizumab improves safety in dabigatran-treated patients. Continued education about the availability and appropriate use of idarucizumab is necessary in Asia.